Investigational drug · Phase 2
Intravitreal of Ultevursen
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "Intravitreal of Ultevursen"
First trial start
2024
Dec 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Intravitreal of Ultevursen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa (RP)
- Usher Syndrome Type 2
- Deaf Blind
- Retinal Disease
- Eye Diseases, Hereditary
- Eye Disorders Congenital
- Vision Disorders
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Intravitreal of Ultevursen" as an intervention, largest first.
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneActive, not recruiting
Laboratoires TheaIndustry
NCT06627179 · 81 participants (planned) · Start Dec 11, 2024 · Primary completion Jul 2028
Drug: Intravitreal Injection of Ultevursen · For: Retinitis Pigmentosa (RP); Usher Syndrome Type 2; Deaf Blind and 4 more
Sites: San Francisco, California; Miami, Florida; Atlanta, Georgia · 26 sites in all
- Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneNot yet recruiting
Laboratoires TheaIndustry
NCT07796646 · 81 participants (planned) · Start Oct 5, 2026 · Primary completion Feb 28, 2030
Drug: Intravitreal Injection of Ultevursen · For: Retinitis Pigmentosa (RP); Usher Syndrome Type 2; Deaf Blind and 4 more
- Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)Pivotal-lookingTerminated
Laboratoires TheaIndustry
NCT05158296 · 7 participants · Start Dec 8, 2021 · Primary completion Oct 12, 2022
Drug: Ultevursen · For: Retinitis Pigmentosa; Usher Syndrome Type 2; Deaf Blind and 5 more
Sites: San Diego, California; San Francisco, California; Miami, Florida · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Retinitis Pigmentosa (RP)
- NPI-001N-Acetylcysteine AmidePhase 35 trials
Nacuity Pharmaceuticals, Inc. · Retinitis Pigmentosa (RP), Usher Syndrome, Alzheimer´s Disease
- RTx-015Phase 31 trial
Ray Therapeutics, Inc. · Retinitis Pigmentosa (RP), Inherited Retinal Diseases
- OpCT-001Phase 21 trial
BlueRock Therapeutics · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome
- SPVN20Phase 21 trial
SparingVision · Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.